EntryPoint Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

EntryPoint Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-862	Closed	-$43.3K	–	1342
2024 Q1	$43.3K	Sell	862 -860	-50%	-$46.7K	0.04%	829
2023 Q4	$104K	Buy	+1,722	New	+$88.8K	0.1%	365

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

EntryPoint Capital's MLTX Position: Q2 2024 in Review

EntryPoint Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2024, closing a stake of 862 shares — an estimated $43.3K sold.

EntryPoint Capital first reported a position in MLTX in Q4 2023 and held it in 2 quarters. The position peaked at $104K in Q4 2023. 111 funds tracked by Wall St. Rank hold MLTX as of Q2 2024.

EntryPoint Capital reported no remaining MoonLake Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 862 MoonLake Immunotherapeutics shares in Q2 2024, an estimated $43.3K.
EntryPoint Capital first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's MoonLake Immunotherapeutics position peaked at $104K in Q4 2023.
111 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.